Lydia Roy
Inserm(FR)Université Paris-Est Créteil(FR)University Medical Center(US)Centre Hospitalier Universitaire Henri-Mondor(FR)Université de Poitiers(FR)Assistance Publique – Hôpitaux de Paris(FR)Centre Léon Bérard(FR)Hôpitaux Universitaires Henri-Mondor(FR)
Publications by Year
Research Areas
Chronic Myeloid Leukemia Treatments, Eosinophilic Disorders and Syndromes, Chronic Lymphocytic Leukemia Research, Myeloproliferative Neoplasms: Diagnosis and Treatment, Acute Myeloid Leukemia Research
Most-Cited Works
- → Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs(2012)444 cited
- → Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease(2013)408 cited
- → Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib(2008)352 cited
- → Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study(2020)334 cited
- → Survival advantage from imatinib compared with the combination interferon-α plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials(2006)216 cited